BSX · News · 20260825N

Revenue Performance and Mix

BOSTON SCIENTIFIC CORP · 2026-08-25 · Importance 36 · Surprise 40

Boston Scientific reported double-digit year-over-year revenue growth in the period discussed. The company surpassed second-quarter revenue expectations, according to third-party reporting. The revenue performance was cited alongside solid profitability despite broader medtech-sector selling pressure.

Key facts

• Boston Scientific surpassed second-quarter revenue and EPS expectations. source
• The company reported double-digit revenue growth. source
• Boston Scientific stock rose 1.73% to $49.86 on the reported trading day. source
• Shares were trading at $49.01 against a fair value of $64.33, per TD Cowen's note. source
• TD Cowen cited a PEG ratio of 0.42 for Boston Scientific. source
• Boston Scientific's stock is trading near 52-week lows. source
• The company's stock closed significantly below its 52-week high. source
• Analysts maintain a "Moderate Buy" rating on Boston Scientific. source